Abstract
Some patients may have partial or complete deficiency of dihydropyrimidin dehydrogenase (DPD) and be more likely to experience severe toxicity with 5-fluorouracil. Since the spring of 2020, the Danish Medicines Agency has recommended genotype or phenotype testing before treatment with a fluoropyrimidine, but the most appropriate test strategy is debated. In this review, we present polymorphisms in the genes coding for DPD and summarise the evidence for DPD-enzyme deficiency testing and pharmacokinetic guided dosing.
| Translated title of the contribution | Phenotype- or genotype test for dihydropyrimidin dehydrogenase deficiency before treatment with a fluoropyrimidine |
|---|---|
| Original language | Danish |
| Article number | V07200556 |
| Journal | Ugeskrift for Laeger |
| Volume | 183 |
| Issue number | 20 |
| ISSN | 0041-5782 |
| Publication status | Published - 8. Feb 2021 |